Literature DB >> 10482189

Current management of metastatic breast cancer.

E A Perez1.   

Abstract

The medical approach to the management of metastatic breast cancer has changed through the years following the introduction of new cytotoxic agents and the demonstration of their antitumor activity. In general, combination drug regimens are the initial treatments of choice when chemotherapy is indicated for patients with metastatic breast cancer. However, the single-agent activity of some of the newer agents rivals that of older combination chemotherapy treatments. Compared with older therapies, improved objective response rates and/or improved duration of response recently have been reported in studies evaluating optimal dosing and sequencing of these newer agents, alone or in combination with other drugs. Although there is no rigid standard for the sequencing of therapy for management of metastatic breast cancer, chemotherapy has a role in the treatment program for nearly all patients with this disease. The goal of treatment remains meaningful palliation of patients with complications of progressive cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482189

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

Review 1.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Immune correlates of clinical outcome in melanoma.

Authors:  Graham Pawelec
Journal:  Immunology       Date:  2017-12-20       Impact factor: 7.397

3.  Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

Authors:  Alvaro Moreno-Aspitia; Roscoe F Morton; David W Hillman; Wilma L Lingle; Kendrith M Rowland; Martin Wiesenfeld; Patrick J Flynn; Tom R Fitch; Edith A Perez
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

4.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Authors:  Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.

Authors:  Jae Hong Seo; Hwa Jung Sung; Kyong Hwa Park; In Keun Choi; Sang Cheul Oh; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Ae-Ree Kim; Jae-Bok Lee; Bum Hwan Koo
Journal:  Invest New Drugs       Date:  2008-08-29       Impact factor: 3.850

6.  Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

Authors:  Manon Buijs; Josephina A Vossen; Jean-Francois H Geschwind; Takayoshi Ishimori; James M Engles; Obele Acha-Ngwodo; Richard L Wahl; Mustafa Vali
Journal:  Invest New Drugs       Date:  2008-06-14       Impact factor: 3.850

7.  Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial.

Authors:  Daigo Yamamoto; Satoru Iwase; Yu Tsubota; Noriko Sueoka; Chizuko Yamamoto; Kaoru Kitamura; Hiroki Odagiri; Yoshinori Nagumo
Journal:  Onco Targets Ther       Date:  2012-09-17       Impact factor: 4.147

8.  Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.

Authors:  J Bonneterre; V Dieras; M Tubiana-Hulin; P Bougnoux; M-E Bonneterre; T Delozier; F Mayer; S Culine; N Dohoulou; B Bendahmane
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

9.  Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.

Authors:  V Lorusso; E Crucitta; N Silvestris; A Catino; L Caporusso; A Mazzei; M Guida; A Latorre; D Sambiasi; C D'Amico; F Schittulli; P Calabrese; M De Lena
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.